Involvement of high mobility group box‐1 in imiquimod‐induced psoriasis‐like mice model
Explore this paper's citation graph
Summary
The data suggest that HMGB1 may act as a pro‐inflammatory cytokine, and contribute to the development of IMQ‐induced psoriasis‐like inflammation, and moderated clinical and histological evolvement in theIMQ‐treated skin.
- Type
- article
- Published
- 2017-05-01
- Cited by
- 19
- References
- 25
- OpenAlex
- https://openalex.org/W27943400
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3919092
Keywords
Computer science
References
- Cholinergic Anti-Inflammatory Pathway Activity and High Mobility Group Box-1 (HMGB1) Serum Levels in Patients with Rheumatoid Arthritis
- Interplay between CXCR2 and BLT1 Facilitates Neutrophil Infiltration and Resultant Keratinocyte Activation in a Murine Model of Imiquimod-Induced Psoriasis
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1
- Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes.
- A placebo‐controlled randomized study on the clinical effectiveness, immunohistochemical changes and protoporphyrin IX accumulation in fractionated 5‐aminolaevulinic acid‐photodynamic therapy in patients with psoriasis
- Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life
- Increased serum HMGB1 levels in patients with Henoch–Schönlein purpura
- Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.
- High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
- Vitamin D analog calcipotriol suppresses the Th17 cytokine-induced proinflammatory S100 "alarmins" psoriasin (S100A7) and koebnerisin (S100A15) in psoriasis.
- Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities.
- Enhanced HMGB1 Expression May Contribute to Th17 Cells Activation in Rheumatoid Arthritis
- Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells.
- IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions.
- Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion.
- Glycyrrhizin attenuates rat ischemic spinal cord injury by suppressing inflammatory cytokines and HMGB1
- Pathogenesis and therapy of psoriasis
- Misbehaving macrophages in the pathogenesis of psoriasis.
- Paeoniflorin suppresses vascular damage and the expression of E‐selectin and ICAM‐1 in a mouse model of cutaneous Arthus reaction
- Increased HMGB1 serum levels and altered HMGB1 expression in patients with psoriasis vulgaris
Cited by
- Ghrelin attenuates imiquimod‐induced psoriasiform skin inflammation in mice
- Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation
- Advanced Characterization of Imiquimod-Induced Psoriasis-Like Mouse Model
- The Anti-inflammatory Effects of HMGB1 Blockades in a Mouse Model of Cutaneous Vasculitis
- The Immune Tolerance Role of the HMGB1-RAGE Axis
- Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma
- The role of HMGB1 in inflammatory skin diseases.
- Keratinocyte derived HMGB1 aggravates psoriasis dermatitis via facilitating inflammatory polarization of macrophages and hyperproliferation of keratinocyte.
- Resistin – A Plausible Therapeutic Target in the Pathogenesis of Psoriasis
- Could serum HMGB1 levels be a predictor associated with psoriatic arthritis?
- Damage-Associated Molecular Patterns, a Class of Potential Psoriasis Drug Targets
- HMGB1 regulates Th17 cell differentiation and function in patients with psoriasis
- Combined photodynamic therapy and hollow microneedle approach for effective non-invasive delivery of hypericin for the management of imiquimod-induced psoriasis
- Green preparation and evaluation of the anti‐psoriatic activity of vesicular elastic nanocarriers of kojic acid from Aspergillus oryzae N12: Repurposing of a dermo‐cosmetic lead
- Topical adhesive spatio-temporal nanosystem co-delivering chlorin e6 and HMGB1 inhibitor glycyrrhizic acid for in situ psoriasis chemo-phototherapy
- Intradermal delivery of teriflunomide loaded emulsomes using hollow microneedles for effective minimally invasive psoriasis management.
- HMGB1: new biomarker and therapeutic target of autoimmune and autoinflammatory skin diseases
- NMI promotes the secretion of IL-17 and exacerbates psoriasis.
Related papers
No related papers recorded.